Novo Nordisk AS, a late entrant in the gene editing field, hopes it can leapfrog current competitors in the hemophilia space by linking up with US-based bluebird bio Inc. to develop a one-time, life-long therapy for the condition, starting from childhood.
The Danish group best known for metabolic disease products in diabetes and obesity has been trying to refocus its underperforming biopharm business in recent years
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?